Lin H, Bondy M L, Langford L A, Hess K R, Delclos G L, Wu X, Chan W, Pershouse M A, Yung W K, Steck P A
Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Clin Cancer Res. 1998 Oct;4(10):2447-54.
The frequency of loss of heterozygosity (LOH) around MMAC/PTEN and DMBT1 loci and survival analyses based on the LOH status were assessed in 110 patients with different histological groups of gliomas. Twenty-six of the patients had anaplastic oligodendrogliomas, 31 had anaplastic astrocytomas, and 53 had glioblastomas multiforme (GM). At the DMBT1 locus, LOH was observed very frequently in all three histological groups, with no significant difference in the frequency of LOH among the three histological groups. At the MMAC/PTEN locus, patients with GM exhibited a significantly increased frequency of LOH (72%) compared with patients with anaplastic astrocytomas (29%) or anaplastic oligodendrogliomas (31%) (P < 0.0001). Kaplan-Meier survival plots showed that patients with LOH at the MMAC/PTEN locus had a significantly worse prognosis than did patients without LOH at the MMAC/PTEN locus [hazard ratio (LOH versus non-LOH), 2.65; 95% confidence interval (CI), 1.69-4.46; P < 0.0001]. Cox proportional hazards regression analysis, adjusted for age at surgery and histological grades (GM and non-GM), showed that LOH at the MMAC/PTEN locus was a significant predictor of shorter survival [hazard ratio (LOH versus non-LOH), 2.01; 95% CI, 1.1-3.5; P = 0.018). Our analysis failed to indicate a similar association between the frequency of LOH at the DMBT1 locus and patient survival [hazard ratio (LOH versus non-LOH), 2; 95% CI, 0.37-3.13; P = 0.2]. These results suggest that the DMBT1 gene may be involved early in the oncogenesis of gliomas, whereas alterations in the MMAC/PTEN gene may be a late event in the oncogenesis related to progression of gliomas and provide a significant prognostic marker for patient survival.
在110例不同组织学类型的胶质瘤患者中,评估了MMAC/PTEN和DMBT1基因座周围杂合性缺失(LOH)的频率,并基于LOH状态进行了生存分析。其中26例患者为间变性少突胶质细胞瘤,31例为间变性星形细胞瘤,53例为多形性胶质母细胞瘤(GM)。在DMBT1基因座,在所有三种组织学类型中均频繁观察到LOH,三种组织学类型之间的LOH频率无显著差异。在MMAC/PTEN基因座,与间变性星形细胞瘤患者(29%)或间变性少突胶质细胞瘤患者(31%)相比,GM患者的LOH频率显著增加(72%)(P<0.0001)。Kaplan-Meier生存曲线显示,MMAC/PTEN基因座发生LOH的患者预后明显差于MMAC/PTEN基因座未发生LOH的患者[风险比(LOH与非LOH),2.65;95%置信区间(CI),1.69 - 4.46;P<0.0001]。经手术年龄和组织学分级(GM和非GM)校正的Cox比例风险回归分析显示,MMAC/PTEN基因座的LOH是生存时间缩短的显著预测因素[风险比(LOH与非LOH),2.01;95%CI,1.1 - 3.5;P = 0.018]。我们的分析未能表明DMBT1基因座的LOH频率与患者生存之间存在类似关联[风险比(LOH与非LOH),2;95%CI,0.37 - 3.13;P = 0.2]。这些结果表明,DMBT1基因可能在胶质瘤发生早期就参与其中,而MMAC/PTEN基因的改变可能是与胶质瘤进展相关的发生过程中的晚期事件,并为患者生存提供了一个重要的预后标志物。